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A B S T R A C T
Purpose
Recent advances in imaging, use of prognostic indices, and molecular profiling techniques have
the potential to improve disease characterization and outcomes in lymphoma. International trials
are under way to test image-based response–adapted treatment guided by early interim positron
emission tomography (PET) –computed tomography (CT). Progress in imaging is influencing trial
design and affecting clinical practice. In particular, a five-point scale to grade response using
PET-CT, which can be adapted to suit requirements for early- and late-response assessment with
good interobserver agreement, is becoming widely used both in practice- and response-adapted
trials. A workshop held at the 11th International Conference on Malignant Lymphomas (ICML) in
2011 concluded that revision to current staging and response criteria was timely.
Methods
An imaging working group composed of representatives from major international cooperative
groups was asked to review the literature, share knowledge about research in progress, and
identify key areas for research pertaining to imaging and lymphoma.
Results
A working paper was circulated for comment and presented at the Fourth International Workshop on PET
in Lymphoma in Menton, France, and the 12th ICML in Lugano, Switzerland, to update the International
Harmonisation Project guidance regarding PET. Recommendations were made to optimize the use of
PET-CT in staging and response assessment of lymphoma, including qualitative and quantitative methods.
Conclusion
This article comprises the consensus reached to update guidance on the use of PET-CT for staging
and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and
late-phase trials.
J Clin Oncol 32:3048-3058. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Advances in staging and response assessment of
lymphomas have occurred with the introduction of
prognostic indices,1-4 molecular profiling,5 and
more accurate imaging,6 with the potential to im-
prove disease characterization and treatment selec-
tion. The International Harmonisation Project
(IHP) first published guidelines about the applica-
tion of positron emission tomography (PET) using
[18F]fluorodeoxyglucose (FDG) in lymphoma7 in
2007, and PET was integrated in revised re-
sponse criteria.8
The field has continued to evolve. PET com-
bined with computed tomography (CT) has re-
placed PET alone. Mounting evidence supports the
central role of PET-CT in staging9-18 and response
assessment in Hodgkin (HL)19-27 and non-Hodgkin
lymphomas (NHL).28-34 Multiple international
studies are under way to investigate whether
PET-CT response can be used to guide therapy
to improve patient outcomes.35,36 Concerted ef-
forts have been made to standardize PET-CT
methods37-41 and interpretation in the context of
trials.42 A five-point scale (5-PS), suited to assess
differing degrees of response at mid- and end of
treatment, has been developed to score images.43
This scale was recommended as the standard
reporting tool at the First International Workshop
on PET in Lymphoma in Deauville, France, in 2009,
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and these so-called Deauville criteria have been widely applied in trials
in preference to earlier criteria.44-49 Quantitative applications of FDG-
PET are also recognized as objective tools for response monitoring,50
although accurate measurement relies on consistent methods for ac-
quisition and processing and rigorous quality assurance of equipment
for widespread application.39,51-54
In response to changing requirements for PET-CT, to accommo-
date assessments at staging and during and after treatment, especially
for response-adapted trials, a workshop was convened at the Interna-
tional Conference on Malignant Lymphoma (ICML) in 2011, at-
tended by representatives from major cooperative groups. ICML
working groups were established to update guidelines. The imaging
group reported to colleagues at follow-up workshops at the Fourth
International Workshop on PET in Lymphoma in Menton, France, in
2012 and the 12th ICML in Lugano, Switzerland, in 2013. This article
represents the consensus reached regarding the use of PET-CT in
lymphoma in clinical practice and late-phase trials.
METHODS
The following areas, pertinent to imaging, were identified as requiring updat-
ing at the 2011 workshop:
● Relevance of existing imaging staging, including the influence of bulk
and assessment of bone marrow involvement
● Use of early or interim PET-CT and requirements for standardization
of methods, including reporting
● Potential prognostic value of quantitative analyses using PET and CT
Experts in nuclear medicine and radiology applied to lymphoma undertook a
literature review and shared knowledge about research in progress. Recom-
mendations were formulated as follows (Table 1):
● Based on established current knowledge (type 1)
● To identify emerging applications (type 2)
● To highlight key areas requiring further research (type 3)
Recommendations were presented at the Fourth International Workshop on
PET in Lymphoma, and a working paper was circulated for comment and
updated after presentation at the 12th ICML.
RECOMMENDATIONS
Interpretation of PET-CT Scans
PET-CT is increasingly used for staging and response as-
sessment in lymphoma,6 both for early assessment during
treatment,19,20,22-25,28,29,31,55-59 commonly referred to as interim
PET-CT (iPET),43 and for remission assessment at the end of
treatment.26,27,30,32-34,60,61 Almost all lymphomas are FDG avid62-64
(Table 2), but most published data are related to the use of PET in HL,
diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma
(FL). PET scans are usually reported using visual assessment,43 noting
the location of increased focal uptake in nodal and extranodal sites,
Table 1. Summary of Recommendations
Recommendations
Section 1: Interpretation of PET-CT scans
1. Staging of FDG-avid lymphomas is recommended using visual assessment, with PET-CT images scaled to fixed SUV display and color table; focal uptake
in HL and aggressive NHL is sensitive for bone marrow involvement and may obviate need for biopsy; MRI is modality of choice for suspected CNS
lymphoma (type 1)
2. Five-point scale is recommended for reporting PET-CT; results should be interpreted in context of anticipated prognosis, clinical findings, and other
markers of response; scores 1 and 2 represent CMR; score 3 also probably represents CMR in patients receiving standard treatment (type 1)
3. Score 4 or 5 with reduced uptake from baseline likely represents partial metabolic response, but at end of treatment represents residual metabolic
disease; increase in FDG uptake to score 5, score 5 with no decrease in uptake, and new FDG-avid foci consistent with lymphoma represent treatment
failure and/or progression (type 2)
Section 2: Role of PET-CT for staging
1. PET-CT should be used for staging in clinical practice and clinical trials but is not routinely recommended in lymphomas with low FDG avidity; PET-CT
may be used to select best site to biopsy (type 1)
2. Contrast-enhanced CT when used at staging or restaging should ideally occur during single visit combined with PET-CT, if not already performed; baseline
findings will determine whether contrast-enhanced PET-CT or lower-dose unenhanced PET-CT will suffice for additional imaging examinations (type 2)
3. Bulk remains an important prognostic factor in some lymphomas; volumetric measurement of tumor bulk and total tumor burden, including methods
combining metabolic activity and anatomical size or volume, should be explored as potential prognosticators (type 3)
Section 3: Role of interim PET
1. If midtherapy imaging is performed, PET-CT is superior to CT alone to assess early response; trials are evaluating role of PET response–adapted therapy;
currently, it is not recommended to change treatment solely on basis of interim PET-CT unless there is clear evidence of progression (type 1)
2. Standardization of PET methods is mandatory for use of quantitative approaches and desirable for routine clinical practice (type 1)
3. Data suggest that quantitative measures (eg, SUVmax) could be used to improve on visual analysis for response assessment in DLBCL, but this requires
further validation in clinical trials (type 2)
Section 4: Role of PET at end of treatment
1. PET-CT is standard of care for remission assessment in FDG-avid lymphoma; in presence of residual metabolically active tissue, where salvage treatment
is being considered, biopsy is recommended (type 1)
2. Investigation of significance of PET-negative residual masses should be collected prospectively in clinical trials; residual mass size and location should be
recorded on end-of-treatment PET-CT reports where possible (type 3)
3. Emerging data support use of PET-CT after rituximab-containing chemotherapy in high–tumor burden FL; studies are warranted to confirm this finding in
patients receiving maintenance therapy (type 2)
4. Assessment with PET-CT could be used to guide decisions before high-dose chemotherapy and ASCT, but additional studies are warranted (type 3)
Abbreviations: ASCT, autologous stem-cell transplantation; CMR, complete metabolic response; CT, computed tomography; DLBCL, diffuse large B-cell lymphoma;
FDG, 18Ffluorodeoxyglucose; FL, follicular lymphoma; HL, Hodgkin lymphoma; MRI, magnetic resonance imaging; NHL, non-Hodgkin lymphoma; PET, positron
emission tomography; SUV, standardized uptake value; SUVmax, change in maximum SUV.
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which is distinguished from physiologic uptake and other patterns of
disease with increased FDG uptake including infection and inflamma-
tion,68,69 according to distribution and/or CT characteristics.
Focal FDG uptake within the bone or bone marrow, liver, and
spleen is highly sensitive for involvement in HL70-73 and aggressive
NHL74-77 and may obviate the need for bone marrow biopsy.70,78,79
Diffuse increased uptake may occur with abnormal focal uptake, but
in HL, diffuse uptake without focal activity often represents reactive
hyperplasia70,80 and should not be confused with lymphomatous in-
volvement. PET-CT can miss low-volume involvement, typically 
20% of the marrow,79,80 and coexistent low-grade lymphoma77,81 in
DLBCL, although this rarely affects management.79 The sensitivity of
PET for diffuse marrow involvement is limited in FL,18 mantle-cell
lymphoma, and most indolent lymphomas,77,82 where biopsy is re-
quired for staging.
High physiologic FDG uptake occurs in the brain, and although
intracerebral lymphoma often shows intense uptake,83 leptomenin-
geal disease, which may be diffuse and of low volume, may be missed.
Magnetic resonance imaging (MRI) is preferred to assess suspected
CNS involvement.
PET scans are best reported using a fixed display and color table
scaled to the standardized uptake value (SUV)84 to assist with consis-
tency of reporting, for serial scans, and to reduce the effect of patient
size. The SUV is the radioactivity most commonly corrected for pa-
tient weight and administered activity.
Recommendation. Staging of FDG-avid lymphomas is recom-
mended using visual assessment, with PET-CT images scaled to a fixed
SUV display and color table. Focal uptake in HL and aggressive NHL is
sensitive for bone marrow involvement and may obviate the need for
biopsy. MRI is the modality of choice for suspected CNS lymphoma
(type 1).
Resolution of uptake at sites of initial disease indicates metabolic
response.8 Reduction of uptake may also indicate satisfactory re-
sponse, but the degree of uptake that is indicative of response43 is
dependent on the timing of the scan during treatment85,86 and the
clinical context, including prognosis, lymphoma subtype,21,30,60 and
treatment regimen.22,56 The availability of a baseline scan is considered
optimal for the accuracy of subsequent response assessment.40,43,87,88
The IHP criteria7 specified that uptake should be  the medias-
tinal blood pool for lesions  2 cm or the adjacent background for
smaller lesions to define metabolic response at the end of treatment. In
early-response assessment, treatment is incomplete, so the emphasis is
on the degree of response and a continuous or close-to-continuous
scale is desirable rather than positive or negative response categories.43
Early attempts to address this used three response groups (ie, negative,
minimal residual uptake, and positive).19,57,89,90 Further refinement
led to the development of the 5-PS,42 which better represents different
grades of uptake.
The 5-PS was intended as a simple, reproducible scoring method,
with the flexibility to change the threshold between good or poor
response according to the clinical context and/or treatment strategy.42
For example, a lower level of FDG uptake might be preferred to define
a so-called negative result in a clinical trial exploring de-escalation to
avoid undertreatment. A higher level of uptake might be preferred
to define a so-called positive result in a trial exploring escalation to
avoid overtreatment. The 5-PS has been validated for use at
interim25,28,34,44,58,91-93 and the end of treatment34,94 and was adopted
as the preferred reporting method at the First International Workshop
on PET in Lymphoma in Deauville, France (ie, Deauville criteria),43
and in several international trials.42,44,46-49,95-97
The 5-PS scores the most intense uptake in a site of initial disease,
if present, as follows:
● 1. No uptake
● 2. Uptake  mediastinum
● 3. Uptake  mediastinum but  liver
● 4. Uptake moderately higher than liver
● 5. Uptake markedly higher than liver and/or new lesions
● X. New areas of uptake unlikely to be related to lymphoma
Good interobserver agreement has been reported in HL,42,92,98
DLBCL,93 and FL.34
The UK RAPID (Response Adapted Therapy Using Positron
Emission Tomography in Early-Stage Hodgkin Lymphoma) study
used the 5-PS in patients with early HL. iPET remained an indepen-
dent predictor of 3-year progression-free survival (PFS) on multivari-
able analysis, despite use of a response-adapted design.44 Conservative
scoring was used, with a score of 1 or 2 regarded as complete metabolic
response(CMR);patientswithCMRafterthreecyclesofABVD(doxo-
rubicin, bleomycin, vinblastine, and dacarbazine) were randomly as-
signed to radiotherapy (RT) or no further treatment. Retrospective
analysis of an international cohort of 260 patients with advanced HL
using scores 1, 2, and 3 to define CMR after two ABVD cycles reported
a negative predictive value (NPV) of 94% and positive predictive value
(PPV) of 73% for 3-year PFS.25 iPET and end-of-treatment PET using
scores 1, 2, and 3 for CMR were both independent predictors of 2-year









Mantle-cell lymphoma 83 100
Burkitt’s lymphoma 24 100
Marginal zone lymphoma, nodal 14 100
Lymphoblastic lymphoma 6 100
Anaplastic large T-cell lymphoma 37 94-100
NK/T-cell lymphoma 80 83-100
Angioimmunoblastic T-cell lymphoma 31 78-100
Peripheral T-cell lymphoma 93 86-98
MALT marginal zone lymphoma 227 54-81
Small lymphocytic lymphoma 49 47-83
Enteropathy-type T-cell lymphoma 20 67-100
Marginal zone lymphoma, splenic 13 53-67
Marginal zone lymphoma, unspecified 12 67
Mycosis fungoides 24 83-100
Sezary syndrome 8 100†
Primary cutaneous anaplastic large T-cell lymphoma 14 40-60
Lymphomatoid papulosis 2 50
Subcutaneous panniculitis-like T-cell lymphoma 7 71
Cutaneous B-cell lymphoma 2 0
NOTE. Data adapted,64 with additional updates.18,33,34,65-67
Abbreviations: DLBCL, diffuse large B-cell lymphoma; FDG, 18Ffluorodeoxy-
glucose; FL, follicular lymphoma; HL, Hodgkin lymphoma; MALT, mucosa-associated
lymphoid tissue; NK, natural killer.
Only 27% of cutaneous sites.
†Only 62% of cutaneous sites.
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PFS in a recent prospective study in FL.34 Other studies in HL and
NHL have reported that increasing the threshold to define CMR
improved the PPV while maintaining a high NPV.28,34,91,92,94
Scores 1 and 2 are therefore considered to represent CMR. Score
3 also likely represents CMR at interim25 and good prognosis at com-
pletion of standard treatment.34,94,99 However, in trials where de-
escalation is based on PET response, it may be preferable to consider
score 3 as inadequate response to avoid undertreatment.42
Recommendation. The 5-PS is recommended for reporting
PET-CT. Results should be interpreted in the context of the antici-
pated prognosis, clinical findings, and other markers of response.
Scores 1 and 2 represent CMR. Score 3 also probably represents CMR
in patients receiving standard treatment (type 1).
The terms moderately and markedly were not defined ini-
tially, because there were insufficient data to define scores quanti-
tatively.43 Meanwhile, it is suggested according to published
data25,34,100 that score 4 be applied to uptake  the maximum SUV
in a large region of normal liver and score 5 to uptake 2 to 3 
the maximum SUV in the liver. It is acknowledged that mean liver
SUV may be less influenced by image noise than maximum SUV,
but reproducibility is more dependent on standardizing the loca-
tion and size of the region of interest.101 Work is ongoing to assess
optimal tumor and liver metrics.102 The liver is also affected by
insulin levels, and patient preparation is important with respect to
fasting and timing of insulin administration in diabetics.103 It is
recognized that in Waldeyer’s ring or extranodal sites with high
physiologic uptake or with activation within spleen or marrow (eg,
with chemotherapy or granulocyte colony-stimulating factor
[GCSF]), FDG uptake may be  normal mediastinum and/or liver.
In this circumstance, CMR may be inferred if uptake at sites of
initial involvement is  surrounding normal tissue, even if the
tissue has high physiologic uptake.
Recommendation. Scores 4 and 5 with reduced uptake from
baseline likely represent partial metabolic response, but at the end of
treatment, they represent residual metabolic disease. An increase in
FDG uptake to a score of 5, score 5 with no decrease in uptake, and
new FDG-avid foci consistent with lymphoma represent treatment
failure and/or progression (type 2).
Nonspecific FDG uptake may occur with treatment-related in-
flammation. Patients should be scanned as long after the previous
chemotherapy administration as possible for interim assessment. A
minimum of 3 weeks, but preferably 6 to 8 weeks, after completion of
the last chemotherapy cycle,7 2 weeks after GCSF treatment, or 3
months after RT is recommended.39
Role of PET-CT for Staging
Previous clinical trials have used the Ann Arbor staging system to
select patients and report outcomes.104 Currently, prognostic indices
are mostly used to risk stratify patients at diagnosis to inform therapy,
but most include stage as a factor,1-3,105 so imaging-determined stage
remains relevant.
PET-CT using FDG is more accurate than CT for staging in
HL9,10,106-111 and NHL,11-13,18,112,113 with increased sensitivity, partic-
ularly for extranodal disease.6 Upstaging occurs more often than
downstaging, with management alterations in some patients (Table
3). Management change after upstaging is more common in FL14,15
than other lymphomas, especially for patients with limited disease
on CT.16,17
The intensity of FDG uptake is higher in aggressive than indolent
lymphomas, and FDG PET-CT may be used to target biopsy in pa-
tients with suspected transformation.65,114,115
Recommendation. PET-CT should be used for staging in clinical
practice and clinical trials, but it is not routinely recommended in
Table 3. Studies Comparing PET or PET-CT With CT Alone for Staging of Lymphomas
Study Year PET or PET-CT No. of Patients Disease Upstaging (%) Downstaging (%)
Management
Change (%)
Bangerter et al106 1998 PET 44 HL 12 2 14
Partridge et al107 2000 PET 44 HL 41 7 25
Jerusalem et al108 2001 PET 33 HL 10 10 3
Weihrauch et al109 2002 PET 22 HL 18 0 5
Munker et al110 2004 PET 73 HL 29 3 NS
Naumann et al111 2004 PET 88 HL 13 8 20
Hutchings et al9 2006 Mostly PET-CT 99 HL 19 5 9
Rigacci et al10 2007 Mostly PET 186 HL 14 1 6
Buchmann et al112 2001 PET 52 HL (n  27), NHL (n  25) 8 0 8
Wirth et al113 2002 PET 50 HL (n  19), NHL (n  31) 14 0 18
Raanani et al11 2006 PET-CT 103 HL (n  32), NHL (n  68) 31 1 25
Elstrom et al12 2008 PET-CT 61 HL and NHL 18 0 5
Pelosi et al13 2008 PET 65 HL (n  30), NHL (n  35) 11 5 8
Karam et al14 2006 PET 17 FL 41 0 29
Janikova et al15 2008 Mostly PET 82 FL NS NS 18
Wirth et al16 2008 PET 42 FL stages I-II on CT 29 0 45
Le Dortz et al17 2010 PET-CT 45 FL 8 0 18
Luminari et al18 2013 PET-CT 142 FL 11 1 NS
Abbreviations: CT, computed tomography; FL, follicular lymphoma; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; NS, not stated; PET, positron
emission tomography.
False negative.
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lymphomas with low FDG avidity. PET-CT may be used to select the
best site to biopsy (type 1).
Role of Contrast-Enhanced CT
The CT part of a PET-CT scan may be performed with contrast
enhancement (ceCT) at full dose to obtain a high-quality CT exami-
nation or without contrast using a lower dose. Lower-dose CT is used
to correct for the attenuation of radioactivity within the patient and to
localize abnormalities seen on PET, with less radiation than a full
diagnostic examination.84 Whichever protocol is used, CT must be
acquired during shallow breathing or end of expiration to avoid mis-
registration and artifacts.
Direct comparison of unenhanced lower-dose PET-CT and
cePET-CT suggests management is rarely altered by ceCT, although
ceCT may identify additional findings11,12,116-119 and improve detec-
tion of abdominal or pelvic disease.11,116,117 However, full-dose ceCT
involves additional radiation, which should be considered when de-
ciding which examination to perform. ceCT is desirable for RT plan-
ning performed in the treatment position120 and is required for
accurate nodal measurements for trial purposes.
Small errors in the measurement of FDG uptake in tumor may
occur with contrast media121 because of an effect on attenuation
correction; these errors are unlikely to be clinically important.122
However, contrast may cause errors in comparison of uptake be-
tween tumor and reference sites by causing FDG uptake to be
overestimated in the mediastinum and liver by 10% to 15%.121
Several organizations (eg, European Association Nuclear Medi-
cine, Society Nuclear Medicine, and Radiological Society North
America) recommend that a low-dose CT scan with normal
breathing be performed before a PET scan, followed by full diag-
nostic high-dose ceCT with repositioning of the arms and breath
hold, if quantitative measures and ceCT are required.
In practice, many patients undergo separate ceCT before PET-
CT. If baseline ceCT demonstrates no additional relevant findings,
lower-dose CT during PET-CT examination will be sufficient for
response assessment.
Recommendation. ceCT when used at staging or restaging
should ideally occur during a single visit in combination with PET-
CT, if not already performed. The baseline findings will determine
whether cePET-CT or lower-dose unenhanced PET-CT will suffice
for additional imaging examinations (type 2).
Relevance of Initial Disease Bulk
The presence of bulky disease is a negative prognostic factor in
some lymphomas.1-3,105 Bulk is considered an adverse factor in early-
stage HL123 but not in advanced HL.105 In DLBCL, bulk is predictive of
inferior survival in favorable-prognosis disease124,125 but not in poor-
prognosis disease, probably because its influence is superseded by
other factors reflecting disease burden.126 The longest diameter of the
largest involved node is included in the FL International Prognostic
Index 2.127 Unidimensional measurements are used for bulk, but these
do not assess total tumor burden. Newer methods of contouring are
being developed for CT128,129 and PET130,131 to measure the total
tumor volume. The prognostic value of these methods remains to
be evaluated.
Recommendation. Bulk remains an important prognostic factor
in some lymphomas. Volumetric measurement of tumor bulk and
total tumor burden, including methods combining metabolic activity
and anatomic size or volume, should be explored as potential prog-
nosticators (type 3).
Role of iPET
Interim imaging is frequently performed in clinical practice and
trials and is recommended by some international guidelines.123 The
purpose is to ensure the effectiveness of treatment and exclude the
possibility of progression. PET-CT shows metabolic response earlier
than anatomic response and has the potential to replace CT. Studies
have shown that iPET is a strong prognostic indicator in HL19-25,132
and aggressive NHL,28,29,31,55,57,59,133 outperforming the International
Prognostic Score22 and International Prognostic Index.57 These find-
ings highlight the potential of using iPET to tailor treatment according
to individual response. However, it is important to emphasize that
there is no conclusive evidence that changing treatment according to
iPET improves outcome,6,35 a question currently being addressed in
clinical trials worldwide.35
There is a preponderance of data reporting the predictive value of
iPET, most often after two cycles in HL20,22-25 (Appendix Table A1,
online only). In DLBCL, early indication of poor response is especially
important because salvage treatment of progressive or relapsed disease
is less effective in the rituximab era.134 However, although early data
favored iPET,55,57,59 more recent data have suggested iPET is less
predictive for response with immunochemotherapy30-32,58,135,136
(Appendix Table A2, online only), and end-of-treatment PET is a
better predictor.
Visual assessment with iPET in HL results in consistently high
NPV, with  2-year PFS of approximately 95%, and acceptable PPV,
with PFS between 13% and 27%,19,22,24,92 for advanced disease treated
with ABVD. Initial reports using visual analysis for iPET in DLBCL
were favorable,55,57,59 but more recent studies have demonstrated
good NPV, with  2-year PFS rates of 73% to 86% for patients with
so-called negative scans, but more variable PPV. PFS for PET-positive
patients in recent studies has ranged from 18% to 74%.28-32,93,135-137
The drop in PPV may be related to improved outcomes with ritux-
imab or better supportive care126,138 or may possibly occur because
so-called false-positive metabolic activity is more frequent with im-
munotherapy.30 A different cutoff or combination of factors may be
required for modern management of DLBCL.
Recommendation. If midtherapy imaging is performed,
PET-CT is superior to CT alone to assess early response. Trials are
evaluating the role of PET response–adapted therapy. Currently,
changing treatment solely on the basis of iPET-CT is not recom-
mended, unless there is clear evidence of progression (type 1).
The use of quantitation to improve on visual assessment has been
explored in DLBCL. Change in the maximum SUV (SUVmax) in
tumor before and after treatment has been evaluated as a measure of
response. Receiver operator curve analysis in 92 patients with DLBCL
scanned after two cycles and 80 patients scanned after four identified
optimum thresholds for percentage change in SUVmax for predicting
event-free survival (EFS).85,86 A retrospective analysis applied to a trial
where treatment was adapted according to visual assessment with
iPET reported that SUVmax at two and four cycles was predictive of
PFS, whereas visual analysis was not.139 Other groups have also re-
ported that SUVmax predicts response, but with thresholds rang-
ing from 66% to 91%,58,91,137,139 suggesting that consistency in
scanning protocols, matching conditions for serial scans, and
proper calibration and scanner maintenance are mandatory for
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general application.38,39,41,51-53,121,140 The optimum cutoff is also
likely influenced by timing, with a tendency for a higher cutoff later
during treatment.86 Although the goal of quantitation is more
objective assessment, it remains necessary to integrate with clinical
information to exclude confounding variables.39
The SUVmax analysis is being prospectively applied in
the PETAL (Positron Emission Tomography Guided Therapy of Ag-
gressive Non-Hodgkin’s Lymphomas) and GAINED (GA in Newly
Diagnosed Diffuse Large B Cell Lymphoma) studies exploring
response-adapted treatment with immunochemotherapy.50 Combin-
ing SUVmax with CT metrics in early nonbulky HL141 and with
age-adjusted International Prognostic Index in DLBCL has been re-
ported to improve response prediction.58 Another measure proposed
is SUVpeak, a 1-cm3 volume containing the hottest area of tumor,102
which may be less sensitive to noise and resolution and possibly more
reproducible. Changes in the metabolic tumor volume (MTV) and
total lesion glycolysis (TLG) calculated as MTV  SUVmean are
additional exploratory measures.102 However, preliminary reports
have suggested changes in MTV and TLG are not predictive in
DLBCL.131,142 The results of the UK National Cancer Research Insti-
tute PET R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) substudy measuring PFS in 200 patients
with DLBCL where clinicians were blinded to iPET are awaited.40,143
This and other studies may provide insight into whether quantitation
will improve the performance of iPET in DLBCL.139
Recommendation. Standardization of PET methods is manda-
tory for the use of quantitative approaches and desirable for routine
clinical practice (type 1). Data suggest that quantitative measures (eg,
SUVmax) could be used to improve on visual analysis for response
assessment in DLBCL, but this requires further validation in clinical
trials (type 2).
Role of PET at the End of Treatment
End-of-treatment remission assessment is more accurate with
PET-CT than CT alone in patients with HL,26,60 DLBCL,30,32 and
high–tumor burden FL33,34 (Appendix Table A3, online only). High
accuracy for PET-CT has been reported in patients after treatment
with ABVD26 and BEACOPP (bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and prednisone)27 for
advanced HL. In a study where PET was used to guide RT, patients
treated with BEACOPP (but no RT) with a PET-negative positive
response had PFS equivalent to that of patients with complete re-
sponse (CR) or unconfirmed CR.27 In aggressive NHL, studies involv-
ing  300 patients have reported consistently high NPV of 80% to
100% but more variable PPV of 50% to 100%.30,32,61,135,144,145 In the
presence of residual metabolically active tissue, if salvage treatment is
being considered, a biopsy may be required. If residual disease is
considered unlikely, the scan could be repeated later.
Recommendation. PET-CT is the standard of care for remission
assessment in FDG-avid lymphoma. For HL and DLBCL, in the pres-
ence of residual metabolically active tissue, where salvage treatment is
being considered, a biopsy is recommended (type 1).
The significance of a residual mass if CMR is achieved is unclear,
with some reports suggesting improved outcomes when CMR is asso-
ciated with a radiologic CR in HL and DLBCL,146-149 whereas others
suggest outcomes are unaffected by the presence of a residual
mass.23,27,150 It is proposed that the size of the residual mass be re-
corded where possible, and if relapse occurs, it should be documented
whether this occurred within the residual mass.
Recommendation. Investigation of the significance of PET-
negative residual masses should be collected prospectively in clinical
trials. Residual mass size and location should be recorded on end-of-
treatment PET-CT reports where possible (type 3).
In FL, PET predicts inferior outcomes in patients with
high tumor burden who remain PET positive after first-line
immunochemotherapy.33,34 Post-treatment PET seems to be a
better predictor than iPET.34 Currently, data are insufficient
regarding assessment after maintenance therapy.151 This sug-
gests a potential role for PET in evaluating new approaches in
response-adapted studies in FL after first-line treatment with
rituximab-containing chemotherapy.151
Recommendation. Emerging data support the use of PET-CT
after rituximab-containing chemotherapy in high–tumor burden FL.
Studies are warranted to confirm this finding in patients receiving
maintenance therapy (type 2).
Assessment Before High-Dose Chemotherapy and
Autologous Stem-Cell Transplantation
Various studies have reported that PET-CT using FDG is prog-
nostic in patients with relapsed or refractory HL or DLBCL after
salvage chemotherapy before high-dose chemotherapy and autolo-
gous stem-cell transplantation (ASCT)152-157 and is superior to CT
alone.158 Three-year PFS and EFS rates of 31% to 41% have been
reported for patients with PET-positive scans, compared with 75% to
82% for patients with PET-negative scans.152-157
PET may have a role in selecting patients for high-dose chemo-
therapy and ASCT after salvage treatment159 and in identifying pa-
tients with poor prognosis who could benefit from alternative
regimens or consolidation.160 PET could also be used as a surrogate
end point to test the addition of novel therapies to current reinduc-
tion regimens.161
Recommendation. Assessment with PET-CT could be used to
guide decisions before high-dose chemotherapy and ASCT, but addi-
tional studies are warranted (type 3).
PET-CT in Subtypes Other Than HL, DLBCL, and FL
Small retrospective studies have suggested that post-treatment
scans can predict survival in treatment of mantle-cell lymphoma.65 In
primary mediastinal B-cell lymphoma, a recent prospective study
reported that 54 (47%) of 115 patients achieved CMR after first-line
chemotherapy,94 and a PET response–adapted approach is currently
being tested (IELSG-37 [International Extranodal Lymphoma Study
Group]).48 However, another study involving 51 patients treated with
dose-adjustedEPOCH(etoposide,prednisone,vincristine,cyclophos-
phamide, and doxorubicin) plus rituximab reported that 10 of 15
patients had FDG uptake 6 weeks after treatment, which later dimin-
shed or stabilized, suggesting treatment-related inflammation with
this regimen.162 There are limited data regarding T-cell lymphomas,
with higher uptake reported in more aggressive subtypes and lower
uptake in cutaneous lymphomas.163 In mycosis fungoides, higher
uptake has been reported in the presence of large-cell transforma-
tion66,163 and extracutaneous disease, which adversely affects progno-
sis.66,164 There are few data on response assessment; one report in
noncutaneous mature natural killer/T-cell lymphoma suggested iPET
was predictive of response,165 whereas another found that neither
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interim nor end-of-treatment PET were predictive.67 Prospective
studies are warranted.
DISCUSSION
In response to developments involving PET-CT, recommendations
from the ICML imaging group have been made to update practice.
These include guidance on reporting of PET-CT for staging and re-
sponse assessment of HL, DLBCL, and aggressive FL using the 5-PS.
PET-CT is recommended for midtreatment assessment in place of CT
alone, if imaging is clinically indicated, and for remission assessment.
Quantitative imaging parameters for assessing disease burden and
response should be explored as potential prognosticators. The stan-
dardization of PET-CT methods is mandatory for quantitative analy-
sis and desirable for best clinical practice.
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Lawrence H. Schwartz, Emanuele Zucca, Richard I. Fisher, Rodney J.
Hicks, Michael J. O’Doherty, Alberto Biggi, Bruce D. Cheson
Collection and assembly of data: Sally F. Barrington, N. George
Mikhaeel, Lale Kostakoglu, Michel Meignan, Martin Hutchings, Stefan
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Hutchings et al19 2005 85 I-IV Mostly ABVD (n  79) 2-3 72 5 92 39
Hutchings et al20 2006 77 I-IV Mostly ABVD (n  70) 2 61 2 96 0
Gallamini et al22 2007 260 IIB-IV Mostly ABVD (n  249) 2 210 2 96 6
Markova et al56 2009 50 IIB-IV BEACOPP 4 36 2 97 86
Cerci et al23 2010 104 I-IV ABVD 2 74 3 90 53
Barnes et al60 2011 96 I-II (nonbulky) ABVD 2-4 79 4 91 87
Zinzani et al24 2012 304 I-IIA (n  147) ABVD 2 128 9 95 31
IIB-IV (n  157) 2 123 9 89 29
Biggi et al25 2013 260 IIB-IV ABVD 2 215 3 95 28
Abbreviation: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, and prednisone; EFS, event-free survival; HL, Hodgkin lymphoma; PET, positron emission tomography; PFS, progression-free survival.
Prospective study.















Spaepen et al59 2002 70 Mostly CHOP (n  56) 3-4 37 2 85 0
Haioun et al55 2005 90 CHOP or ACVBP/ACE (n  53) plus rituximab (n  37) 2 54 2 82 43
Mikhaeel et al57 2005 121 Mostly CHOP (n  97) 2-3 69 5 89 16
Cashen et al135 2011 50 R-CHOP 2-3 26 2 85 63
Micallef et al32 2011 76 ER-CHOP 2 60 2 73 60
Yang et al28 2011 159 R-CHOP 3-4 116 3 86 29
Yoo et al136 2011 155 R-CHOP 2-4 100 3 84 66
Zinzani et al29 2011 91 Mostly R-CHOP (n  66), rituximab (n  91) Midtreatment 56 5 75 18
Safar et al31 2012 112 R-CHOP (n  81), R-ACVBP (n  31) 2 70 3 84 47
Pregno et al30 2012 88 R-CHOP 2-4 66 2 85 72
Nols et al58 2013 73 R-CHOP (n  48), R-miniCHOP (n  8), ACVBP (n  17),
CHOP (n  1)
3-4 53 2 84 47
Abbreviations: ACE, doxorubicin, cyclophosphamide, and etoposide; ACVBP, doxorubicin, cyclophosphamide, vincristine, bleomycin, and prednisone; CHOP,
cyclophosphamide, doxorubicin, vincristine, and prednisone; E, etoposide; EFS, event-free survival; NHL, non-Hodgkin lymphoma; PET, positron emission
tomography; PFS, progression-free survival; R, rituximab.
Prospective study.
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Table A3. Studies, Including  50 With Homogenous Patient Populations With HL or Aggressive NHL or FL, Reporting Outcomes
According to Visual Assessment With End-of-Treatment PET
Study Year
No. of










Spaepen K et al: Br J Haematol
115:272-278, 2001 2001 60 IIA-IVB HL 55 100 91 2 91 0
Cerci et al26 2010 50 I-IV HL (patients in CRu/PR on CT) 23 100 92 — NS NS
Engert et al27† 2012 739 IIB-IV HL 548 95 NA 5 92 86†
Barnes et al60 2011 96 I-II nonbulky HL 83 94 46 4 94 54
Spaepen et al61 2001 93 Aggressive NHL 50 100 70 — NS NS
Micallef et al32 2011 69 DLBCL 61 90 50 2 78 50
Pregno et al30 2012 88 DLBCL 77 100 82 2 83 64
Trotman et al33 2011 122 High–tumor burden FL 90 NS NS 3.5 71 33
Dupuis et al34 2012 106 High–tumor burden FL 83 NS NS 2 87 51
Abbreviations: CRu, unconfirmed complete response; CT, computed tomography; DLBCL, diffuse large B-cell lymphoma; EFS, event-free survival; FL, follicular
lymphoma; FTF, freedom from treatment failure; HL, Hodgkin lymphoma; NA, not applicable; NHL, non-Hodgkin lymphoma; NPV, negative predictive value; NS, not
stated; PET, positron emission tomography; PFS, progression-free survival; PPV, positive predictive value; PR, partial response.
Prospective study.
†Treatment guided by end-of-treatment PET.
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Fig A1. (A) Pretreatment scan: computed tomography, positron emission tomography, and fused images showing disease in left neck (arrow). (B) Example of score
1: complete metabolic response with no uptake in normal-size lymph nodes at site of initial disease in left neck (arrow).
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Fig A2. (A) Pretreatment scan: computed tomography, positron emission tomography, and fused images showing disease in left axilla. (B) Example of score 2: residual
uptake of intensity  mediastinal blood pool in lymph nodes in left axilla (arrow). Maximum standardized uptake value (SUVmax) in lymph nodes was 1.2; SUVmax in
mediastinal blood pool was 1.7.
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Fig A3. (A) Pretreatment scan: computed tomography, positron emission tomography, and fused images showing disease in right neck and mediastinum (arrow). (B)
Example of score 3: residual uptake of intensity  mediastinal blood pool but  liver in residual mediastinal mass (arrow). Maximum standardized uptake value
(SUVmax) in mass was 1.7; SUVmax in liver was 2.2.
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Fig A4. (A) Pretreatment scan: computed tomography, positron emission tomography, and fused images showing disease in mediastinum. (B) Example of score 4:
residual uptake of intensity  liver in residual mediastinal mass (arrow). Maximum standardized uptake value (SUVmax) in mass was 4.5; SUVmax in liver was 3.2.
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Fig A5. (A) Pretreatment scan: computed tomography, positron emission tomography, and fused images showing disease in right neck, mediastinum, and right axilla.
(B) Example of score 5: residual uptake in mediastinum with intensity markedly higher than normal liver. Maximum standardized uptake value (SUVmax) in mass was
13.0; SUVmax in liver was 2.3.
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